Recapping H1’s Global Impact in 2021 and How They Will Impact 2022

H1 Founder and CEO, Ariel Katz Katz sat down with Fierce editor, Rebecca Willumson, to share the company’s recent Carevoyance acquisition, expanded product portfolio, and how 2022 will be a year focused on continuing to connect the healthcare ecosystem, and bringing health equity diversity and inclusion to clinical trials and patient populations with the H1 platform and suite of products.